Mednet Logo
CommunityRheumatology

How do you approach hypogammaglobulinemia monitoring when using obinutuzumab for refractory nonrenal SLE patients?

Furie et al., PMID 41789864 Does their other immunosuppressive medication regimen influence your approach at all?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Nephrology · Johns Hopkins University
Answered on

I would start with a baseline evaluation that includes quantitative IgG levels, HBV serologies, including HBsAg and anti-HBc, to assess reactivation risk even if HBsAg-negative, and a CBC with differential. Before treatment, I would make sure all non-live vaccines are completed, and I would avoid li...

Join for free or sign in to see the full answer